Projectes

Codi

FI22/00218

Investigador/a principal

Mercedes Serrano Gimaré

Rol

Individual

Any d'inici

2023

Any de finalització

2026

Import total

89900€

Objectius

ISCIII_Mercedes Serrano

Codi

CP22/00029 (Proyecto)

Investigador/a principal

Ignacio Aznar Lou

Rol

Individual

Any d'inici

2023

Any de finalització

2026

Import total

40000€

Objectius

ISCIII_Ignacio Aznar

Codi

CP22/00029

Investigador/a principal

Ignacio Aznar Lou

Rol

Individual

Any d'inici

2023

Any de finalització

2026

Import total

268600€

Objectius

ISCIII_Ignacio Aznar

Codi

RYC2021-033369-I

Investigador/a principal

Pablo Vidal-Ribas Belil, Montserrat Dolz Abadia

Rol

Individual

Any d'inici

2022

Any de finalització

2027

Import total

236350€

Objectius

MINISTERIO DE CIENCIA E INNOVACIÓN_Pablo Vidal

Codi

101057655

Investigador/a principal

Raffaele Fiorillo

Rol

Participant

Any d'inici

2022

Any de finalització

2026

Import total

354125€

Objectius

Health services are increasingly moving towards a treatment continuum aligned with the patient journey. This transition will critically depend on the successful deployment of trustworthy AI-enhanced technologies that are accurate, secure, and trusted. The AISN project will develop and validate operating procedures and guidelines for integrating AI in a healthcare continuum, focussing on
post-stroke rehabilitation. AISN delivers a representative AI health platform built from integrating validated platforms for data acquisition and access, clinical interpretation, whole-brain simulation, clinically validated intervention delivery and optimization and model-based prediction. The AISN integrated platform will be validated in the clinical context of rehabilitation in the outpatient and
at-home phase and facilitate a concrete assessment of the fundamental ways in which AI-enhanced clinical decision-support will change the care pathway and the formulation of novel AI compatible treatment guidelines. AISN ensures an ethical approach by developing legal and ethical guidelines for the robust, fair, and trustworthy deployment of AI in health and validating acceptance and
transparency of its solutions. Building on the AISN platform, the project will test current standard operating procedures for integrating AI in health care and formulate and validate new ones where needed. The AISN guidelines and procedures will emphasize the evidence base and safety of clinical interventions, transparency, prognostics at varying time-scales, personalization of
interventions, access to disease-specific information by clinicians, patients and their carers, and assure that the potential of AI is fully developed in the service of value-based medicine satisfying standards of security and safety. We will go beyond currently available guidelines and frameworks by emphasizing explainability, AI tools with evolving performance, and the dynamic interaction between users and algorithms.

Codi

FPU2021-02218

Investigador/a principal

Susana Ochoa Güerre

Rol

Individual

Any d'inici

2022

Any de finalització

2026

Import total

93228,29€

Objectius

MINISTERIO DE UNIVERSIDADES_Susana Ochoa

Codi

CP21/00080

Investigador/a principal

Jesus Montero Marín

Rol

Individual

Any d'inici

2022

Any de finalització

2027

Import total

268600€

Objectius

ISCIII_Jesús Montero

Codi

965226

Investigador/a principal

Maria Rubio Valera, Maria Montserrat Gil Girbau

Rol

Participant

Any d'inici

2021

Any de finalització

2026

Import total

167728,75€

Objectius

Healthcare fragmentation is a main cause for delay in cancer diagnosis and treatment, contributing to high and steadily increasing mortality rates in Latin America(LA), particularly among disadvantaged populations. Building on Equity-LA I (GA223123) and II (GA305197), this research focuses on integrated care interventions, which have proven effective at improving early diagnosis of cancer, mostly in HIC, and are also promoted by national cancer plans in LA, but limitedly implemented or evaluated. The objective is to evaluate the contextual effectiveness of scaling-up a multicomponent integrated care intervention to improve early diagnosis of frequent cancers in healthcare networks of Chile, Colombia and Ecuador. Method: This participatory, interdisciplinary and mix-methods implementation research is two-pronged: a) a quasiexperimental design (controlled before and after) with an intervention and a control healthcare network; b) a case study design. Focussing on the most vulnerable socioeconomic population, it develops in four phases: 1) analysis of delays, related factors and contextual barriers to early diagnosis (base-line); 2) adaptation and scaling-up of the intervention (PC
training, fast-track referral pathway and patient information, adapting available ICT tools) in real life; 3) intra-country evaluation of intervention; 4) cross-country analysis. ICT tools will be also adopted in research activities as needed in a Covid-19 on-going or post- pandemic context. Relevance: EquityCancer-LA contributes to H2020 call objectives advancing cancer control policies by generating: 1) robust evidence on contextual effectiveness and costs-effectiveness of an affordable, tailored intervention to reduce diagnostic delays; and a validated strategy for its large-scale implementation in LA and LMICs; 2) novel data on delays and key barriers and facilitators to early diagnosis and inequalities in access; 3) e-tools to improve clinical practice and research on early diagnosis.

Codi

899671

Investigador/a principal

Lourdes Ibañez Toda

Rol

Coordinador

Any d'inici

2021

Any de finalització

2026

Import total

1720031,25€

Objectius

Polycystic Ovary Syndrome (PCOS) is the most prevalent, chronic endocrine-metabolic disorder of adolescents and young women (AYAs), affecting 5-10% of AYAs worldwide. It is the most frequent cause of anovulatory subfertility. There is no approved therapy for PCOS. Standard off-label treatment with oral contraceptives reverts neither the underlying
pathophysiology nor the associated co-morbidities
Pilot studies have generated new insights into the pathophysiology of PCOS, and have thus led to the development of a new approach wherein the PCOS phenotype is reverted without side effects. The novel medication is a fixed, low-dose combination of two insulin sensitisers [Pioglitazone (Pio), Metformin (Met)] and one mixed anti-androgen and antimineralocorticoid (Spironolactone (Spi)] within a single tablet: SPIOMET
SPIOMET4HEALTH will test, in a multicentre Phase II trial, the additive effects of each SPIOMET component, on top of lifestyle measures in AYAs with PCOS. SPIOMET aims at normalising the ovulation rate and endocrine-metabolic status via the reduction of hepato-visceral fat excess, in an early phase of the disorder. This approach is expected to reduce the risk of morbidity (including subsequent anovulatory subfertility), to improve the quality of life, and to lower the economic burden on European healthcare systems.
The consortium clusters the experts from key research groups working on PCOS in AYAs, across Europe. The design of SPIOMET4HEALTH foresees that the patients themselves will be engaged over the entire timespan of the project, and will also contribute to the ultimate study evaluation. The update and validation of PCOS-specific Patient Reported Outcome Measures (PROM) will provide the first large-scale evidence on the psychosocial benefits of the tested treatments.
The collective evidence from SPIOMET4HEALTH, once completed with economic modelling, will lead to conclusions that inform sound decision-making about PCOS across European healthcare systems.